STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

MAZE Form 4: Director reports 28,423-share gift, updated holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics (MAZE) reported an insider transaction by a director. On 10/23/2025, the reporting person made a gift of 28,423 shares of common stock, recorded at $0 as a no‑consideration transfer exempt under Rule 16b‑5.

Following the transaction, the filer beneficially owned 29,624 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is trustee.

Positive

  • None.

Negative

  • None.
Insider HOMCY CHARLES J
Role Director
Type Security Shares Price Value
Gift Common Stock 28,423 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 29,624 shares (Direct); Common Stock — 7,422 shares (Indirect, By Trust)
Footnotes (1)
  1. The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5. These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is the trustee.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HOMCY CHARLES J
(Last) (First) (Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/23/2025 G(1) 28,423 D $0 29,624 D
Common Stock 7,422 I By Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5.
2. These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is the trustee.
/s/ Courtney Phillips, as attorney-in-fact 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did MAZE disclose in this Form 4?

A director reported a gift of 28,423 MAZE common shares on 10/23/2025 at $0 as a no‑consideration transfer exempt under Rule 16b‑5.

How many MAZE shares does the insider hold after the transaction?

After the gift, the insider held 29,624 shares directly and 7,422 shares indirectly through a revocable trust.

What was the transaction code on the Form 4?

The transaction was coded G, which denotes a gift.

What exemption was cited for the gift?

The filing states the gift is exempt pursuant to Rule 16b‑5.

Who holds the indirect MAZE shares?

The Charles J. Homcy Revocable Trust UA 11/4/1998, for which the reporting person serves as trustee.

What is the insider’s relationship to MAZE?

The reporting person is a Director of Maze Therapeutics, Inc.